Market Overview

UPDATE: Burrill Initiates Sangamo Biosciences at Market Outperform

Related SGMO
Sangamo BioSciences Announces Presentation At The 2015 Stem Cell Meeting On The Mesa - 2:30pm PT on Wednesday, October 7, 2015
Sangamo BioSciences Reports Updated Clinical Data from ZFP Therapeutic® Program for HIV/AIDS at the 2015 Interscience Conference of Antimicrobial Agents and Chemotherapy

Burrill initiated coverage on Sangamo Biosciences (NASDAQ: SGMO) with a Market Outperform rating and a $28.00 price target.

Burrill noted, "We believe Sangamo's innovative genome editing approach could provide novel and transformative therapeutics, which could revolutionize the treatment of genetic disorders. … We believe there is a significant upside to our valuation, given the additional opportunities embedded in the platform, not to mention ex-U.S. markets, which aren't included in our calculation."

Sangamo Biosciences closed at $8.82 on Friday.

Latest Ratings for SGMO

Sep 2015JefferiesMaintainsBuy
Apr 2015BMO CapitalInitiates Coverage onOutperform
Sep 2014JefferiesInitiates Coverage onBuy

View More Analyst Ratings for SGMO
View the Latest Analyst Ratings

Posted-In: BurrillAnalyst Color Initiation Analyst Ratings


Related Articles (SGMO)

View Comments and Join the Discussion!

Get Benzinga's Newsletters